| Estimating the medical care costs of obesity in the United States: Systematic review, meta-analysis, and empirical analysis DD Kim, A Basu Value in Health 19 (5), 602-613, 2016 | 486 | 2016 |
| Perspective and costing in cost-effectiveness analysis, 1974–2018 DD Kim, MC Silver, N Kunst, JT Cohen, DA Ollendorf, PJ Neumann PharmacoEconomics 38 (10), 1135-1145, 2020 | 164 | 2020 |
| Preventable Cancer Burden Associated With Poor Diet in the United States FF Zhang, F Cudhea, Z Shan, DS Michaud, F Imamura, H Eom, M Ruan, ... JNCI Cancer Spectrum 3 (2), pkz034, 2019 | 137 | 2019 |
| Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low-and Middle-Income Countries: Trends in Cost-per-DALY Studies AA Leech, DD Kim, JT Cohen, PJ Neumann Value in Health 21 (7), 759-761, 2018 | 136 | 2018 |
| Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma JD Stein, DD Kim, WW Peck, SM Giannetti, DW Hutton Archives of Ophthalmology 130 (4), 497-505, 2012 | 126 | 2012 |
| Future Directions for Cost-effectiveness Analyses in Health and Medicine PJ Neumann, DD Kim, TA Trikalinos, MJ Sculpher, JA Salomon, ... Medical Decision Making 38 (7), 767-777, 2018 | 77 | 2018 |
| Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema JD Stein, PA Newman-Casey, DD Kim, KH Nwanyanwu, MW Johnson, ... Ophthalmology 120 (9), 1835-1842, 2013 | 68 | 2013 |
| The influence of time horizon on results of cost-effectiveness analyses DD Kim, CL Wilkinson, EF Pope, JD Chambers, JT Cohen, PJ Neumann Expert Review of Pharmacoeconomics & Outcomes Research 17 (6), 615-623, 2017 | 66 | 2017 |
| Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence DD Kim, DW Hutton, AA Raouf, M Salama, A Hablas, IA Seifeldin, ... Global Public Health 10 (3), 296-317, 2015 | 64 | 2015 |
| Trends and disparities in cardiometabolic health among US adults, 1999-2018 M O’Hearn, BN Lauren, JB Wong, DD Kim, D Mozaffarian Journal of the American College of Cardiology 80 (2), 138-151, 2022 | 60 | 2022 |
| Specialty Drug Coverage Varies Across Commercial Health Plans In The US JD Chambers, DD Kim, EF Pope, JS Graff, CL Wilkinson, PJ Neumann Health Affairs 37 (7), 1041-1047, 2018 | 59 | 2018 |
| Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter? X Feng, DD Kim, JT Cohen, PJ Neumann, DA Ollendorf International Journal of Technology Assessment in Health Care 36 (2), 96-103, 2020 | 50 | 2020 |
| Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic: Study reviews alternative pricing strategies (cost-recovery models … PJ Neumann, JT Cohen, DD Kim, DA Ollendorf Health Affairs 40 (1), 53-61, 2021 | 44 | 2021 |
| Prevention of non-communicable disease: best buys, wasted buys, and contestable buys W Isaranuwatchai, Y Teerawattananon, RA Archer, A Luz, M Sharma, ... BMJ 368 (m141), 2020 | 41 | 2020 |
| Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures PJ Neumann, JE Anderson, AD Panzer, EF Pope, BN D'Cruz, DD Kim, ... Gates Open Research 2 (5), 2018 | 39 | 2018 |
| How Does Cost-Effectiveness Analysis Inform Health Care Decisions? DD Kim, A Basu AMA Journal of Ethics 23 (8), 639-647, 2021 | 33 | 2021 |
| Variation in US Private Health Plans’ Coverage of Orphan Drugs JD Chambers, AD Panzer, DD Kim, NM Margaretos, PJ Neumann Am J Manag Care 25 (10), 508-512, 2019 | 31 | 2019 |
| Medicare Part D Coverage of Antiobesity Medications—Challenges and Uncertainty Ahead K Baig, SB Dusetzina, DD Kim, AA Leech The New England Journal of Medicine 388 (11), 961-963, 2023 | 28 | 2023 |
| Analyzing the Cost Effectiveness of Policy Responses for COVID-19: The Importance of Capturing Social Consequences DD Kim, PJ Neumann Medical Decision Making 40 (3), 251-253, 2020 | 27 | 2020 |
| Taking stock of cost-effectiveness analysis of healthcare in China T Butt, GG Liu, DD Kim, PJ Neumann BMJ global health 4 (3), e001418, 2019 | 25 | 2019 |
Peter J. NeumannDirector, Center for the Evaluation of Value and Risk in HealthZweryfikowany adres z tuftsmedicalcenter.org
